FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162080268> ?p ?o ?g. }

• W2162080268 abstract "There is an urgent need for better therapeutics in head and neck squamous cell cancer (HNSCC) to improve survival and decrease treatment morbidity. Recent advances in high-throughput drug screening techniques and next-generation sequencing have identified new therapeutic targets in other cancer types, but an HNSCC-specific study has not yet been carried out. We have exploited data from two large-scale cell line projects to clearly describe the mutational and copy number status of HNSCC cell lines and identify candidate drugs with elevated efficacy in HNSCC. The genetic landscape of 42 HNSCC cell lines including mutational and copy number data from studies by Garnett et al., and Barretina et al., were analyzed. Data from Garnett et al. was interrogated for relationships between HNSCC cells versus the entire cell line pool using one- and two-way analyses of variance (ANOVAs). As only seven HNSCC cell lines were tested with drugs by Barretina et al., a similar analysis was not carried out. Recurrent mutations in human papillomavirus (HPV)-negative patient tumors were confirmed in HNSCC cell lines, however additional, recurrent, cell line-specific mutations were identified. Four drugs, Bosutinib, Docetaxel, BIBW2992, and Gefitinib, were found via multiple-test corrected ANOVA to have lower IC50 values, suggesting higher drug sensitivity, in HNSCC lines versus non-HNSCC lines. Furthermore, the PI3K inhibitor AZD6482 demonstrated significantly higher activity (as measured by the IC50) in HNSCC cell lines harbouring PIK3CA mutations versus those that did not. HNSCC-specific reanalysis of large-scale drug screening studies has identified candidate drugs that may be of therapeutic benefit and provided insights into strategies to target PIK3CA mutant tumors. PIK3CA mutations may represent a predictive biomarker for response to PI3K inhibitors. A large-scale study focused on HNSCC cell lines and including HPV-positive lines is necessary and has the potential to accelerate the development of improved therapeutics for patients suffering with head and neck cancer. This strategy can potentially be used as a template for drug discovery in any cancer type." @default.
• W2162080268 created "2016-06-24" @default.
• W2162080268 creator A5007657275 @default.
• W2162080268 creator A5010487226 @default.
• W2162080268 creator A5019931495 @default.
• W2162080268 creator A5020081585 @default.
• W2162080268 creator A5026373269 @default.
• W2162080268 creator A5032999963 @default.
• W2162080268 creator A5045369743 @default.
• W2162080268 creator A5064201320 @default.
• W2162080268 date "2014-11-27" @default.
• W2162080268 modified "2023-10-09" @default.
• W2162080268 title "Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer" @default.
• W2162080268 cites W1509523524 @default.
• W2162080268 cites W1527088201 @default.
• W2162080268 cites W1550997731 @default.
• W2162080268 cites W1590924049 @default.
• W2162080268 cites W1997338647 @default.
• W2162080268 cites W2004637409 @default.
• W2162080268 cites W2005266572 @default.
• W2162080268 cites W2026548544 @default.
• W2162080268 cites W2029754521 @default.
• W2162080268 cites W2037602535 @default.
• W2162080268 cites W2043398720 @default.
• W2162080268 cites W2049131636 @default.
• W2162080268 cites W2050847569 @default.
• W2162080268 cites W2062312459 @default.
• W2162080268 cites W2067342462 @default.
• W2162080268 cites W2072667482 @default.
• W2162080268 cites W2086955530 @default.
• W2162080268 cites W2091841926 @default.
• W2162080268 cites W2092480028 @default.
• W2162080268 cites W2102042943 @default.
• W2162080268 cites W2105472738 @default.
• W2162080268 cites W2108836663 @default.
• W2162080268 cites W2110366569 @default.
• W2162080268 cites W2114154015 @default.
• W2162080268 cites W2117960515 @default.
• W2162080268 cites W2122357705 @default.
• W2162080268 cites W2125789330 @default.
• W2162080268 cites W2152277972 @default.
• W2162080268 cites W2155384808 @default.
• W2162080268 cites W2158517181 @default.
• W2162080268 cites W2161821474 @default.
• W2162080268 cites W2167841373 @default.
• W2162080268 cites W2168102484 @default.
• W2162080268 cites W2171537806 @default.
• W2162080268 doi "https://doi.org/10.1186/2050-6511-15-66" @default.
• W2162080268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4258049" @default.
• W2162080268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25428177" @default.
• W2162080268 hasPublicationYear "2014" @default.
• W2162080268 type Work @default.
• W2162080268 sameAs 2162080268 @default.
• W2162080268 citedByCount "24" @default.
• W2162080268 countsByYear W21620802682015 @default.
• W2162080268 countsByYear W21620802682016 @default.
• W2162080268 countsByYear W21620802682017 @default.
• W2162080268 countsByYear W21620802682018 @default.
• W2162080268 countsByYear W21620802682019 @default.
• W2162080268 countsByYear W21620802682020 @default.
• W2162080268 countsByYear W21620802682021 @default.
• W2162080268 countsByYear W21620802682022 @default.
• W2162080268 crossrefType "journal-article" @default.
• W2162080268 hasAuthorship W2162080268A5007657275 @default.
• W2162080268 hasAuthorship W2162080268A5010487226 @default.
• W2162080268 hasAuthorship W2162080268A5019931495 @default.
• W2162080268 hasAuthorship W2162080268A5020081585 @default.
• W2162080268 hasAuthorship W2162080268A5026373269 @default.
• W2162080268 hasAuthorship W2162080268A5032999963 @default.
• W2162080268 hasAuthorship W2162080268A5045369743 @default.
• W2162080268 hasAuthorship W2162080268A5064201320 @default.
• W2162080268 hasBestOaLocation W21620802681 @default.
• W2162080268 hasConcept C121608353 @default.
• W2162080268 hasConcept C126322002 @default.
• W2162080268 hasConcept C143998085 @default.
• W2162080268 hasConcept C2776530083 @default.
• W2162080268 hasConcept C2776833033 @default.
• W2162080268 hasConcept C2779438470 @default.
• W2162080268 hasConcept C2780580887 @default.
• W2162080268 hasConcept C502942594 @default.
• W2162080268 hasConcept C60644358 @default.
• W2162080268 hasConcept C71924100 @default.
• W2162080268 hasConcept C86803240 @default.
• W2162080268 hasConceptScore W2162080268C121608353 @default.
• W2162080268 hasConceptScore W2162080268C126322002 @default.
• W2162080268 hasConceptScore W2162080268C143998085 @default.
• W2162080268 hasConceptScore W2162080268C2776530083 @default.
• W2162080268 hasConceptScore W2162080268C2776833033 @default.
• W2162080268 hasConceptScore W2162080268C2779438470 @default.
• W2162080268 hasConceptScore W2162080268C2780580887 @default.
• W2162080268 hasConceptScore W2162080268C502942594 @default.
• W2162080268 hasConceptScore W2162080268C60644358 @default.
• W2162080268 hasConceptScore W2162080268C71924100 @default.
• W2162080268 hasConceptScore W2162080268C86803240 @default.
• W2162080268 hasIssue "1" @default.
• W2162080268 hasLocation W21620802681 @default.
• W2162080268 hasLocation W21620802682 @default.
• W2162080268 hasLocation W21620802683 @default.
• W2162080268 hasLocation W21620802684 @default.
• W2162080268 hasLocation W21620802685 @default.

• next